{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:54:42Z","timestamp":1778608482721,"version":"3.51.4"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jbo.2022.100460","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T19:10:36Z","timestamp":1666984236000},"page":"100460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Preventing osteolytic lesions and osteomyelitis in multiple myeloma"],"prefix":"10.1016","volume":"37","author":[{"given":"Aiken","family":"Dao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul B.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Schindeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jbo.2022.100460_b0005","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","article-title":"Genome instability in multiple myeloma","volume":"34","author":"Neuse","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jbo.2022.100460_b0010","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"Bmj"},{"issue":"3","key":"10.1016\/j.jbo.2022.100460_b0015","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study","volume":"5","author":"Terpos","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jbo.2022.100460_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2011.01721.x","article-title":"The Medical Research Council Myeloma IX trial: the impact on treatment paradigms","volume":"88","author":"Richardson","year":"2012","journal-title":"Eur J Haematol"},{"issue":"10272","key":"10.1016\/j.jbo.2022.100460_b0025","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"The Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.jbo.2022.100460_b0030","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1007\/s12032-010-9542-z","article-title":"Management of disease- and treatment-related complications in patients with multiple myeloma","volume":"27","author":"Gay","year":"2010","journal-title":"Med Oncol"},{"issue":"5","key":"10.1016\/j.jbo.2022.100460_b0035","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"issue":"22","key":"10.1016\/j.jbo.2022.100460_b0040","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1158\/1078-0432.CCR-16-0866","article-title":"New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma","volume":"22","author":"Landgren","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.jbo.2022.100460_b0045","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jbo.2022.100460_b0050","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"Jama"},{"issue":"8","key":"10.1016\/j.jbo.2022.100460_b0055","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrclinonc.2011.63","article-title":"Treatment of multiple myeloma","volume":"8","author":"Rajkumar","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jbo.2022.100460_b0060","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.2586","article-title":"Multiple myeloma: Every year a new standard?","volume":"37 Suppl 1(Suppl 1)","author":"Rajkumar","year":"2019","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.jbo.2022.100460_b0065","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.jbo.2022.100460_b0070","first-page":"220","article-title":"Autologous stem cell transplantation in multiple myeloma","volume":"62","author":"Ricciuti","year":"2020","journal-title":"Panminerva Med"},{"issue":"1","key":"10.1016\/j.jbo.2022.100460_b0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.jbo.2022.100460_b0080","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jbo.2022.100460_b0085","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jbo.2022.100460_b0090","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbo.2022.100460_b0095","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-3-319-40320-5_14","article-title":"Bone Disease in Multiple Myeloma","volume":"169","author":"Eda","year":"2016","journal-title":"Cancer treatment and research"},{"key":"10.1016\/j.jbo.2022.100460_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101929","article-title":"Multiple myeloma: Role of autologous transplantation","volume":"82","author":"Ntanasis-Stathopoulos","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.jbo.2022.100460_b0105","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/MOH.0000000000000538","article-title":"Is autologous stem cell transplantation still relevant for multiple myeloma?","volume":"26","author":"Choi","year":"2019","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"10.1016\/j.jbo.2022.100460_b0110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JOP.19.00335","article-title":"Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies","volume":"16","author":"Parrondo","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.jbo.2022.100460_b0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.23736\/S0031-0808.20.04145-2","article-title":"Chemotherapy-based regimens in multiple myeloma in 2020","volume":"63","author":"Gentile","year":"2021","journal-title":"Panminerva Med"},{"issue":"12","key":"10.1016\/j.jbo.2022.100460_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121629","article-title":"The Anti-CD38 Antibody Therapy in Multiple Myeloma","volume":"8","author":"Petrucci","year":"2019","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.jbo.2022.100460_b0125","first-page":"543","article-title":"Review of thalidomide in the treatment of newly diagnosed multiple myeloma","volume":"3","author":"Cavallo","year":"2007","journal-title":"Ther Clin Risk Manag"},{"issue":"7","key":"10.1016\/j.jbo.2022.100460_b0130","first-page":"826","article-title":"First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma","volume":"89","author":"Cavo","year":"2004","journal-title":"Haematologica"},{"issue":"10245","key":"10.1016\/j.jbo.2022.100460_b0135","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"10214","key":"10.1016\/j.jbo.2022.100460_b0140","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jbo.2022.100460_b0145","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jbo.2022.100460_b0150","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103120","article-title":"Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma","volume":"9","author":"Mateos","year":"2020","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.jbo.2022.100460_b0155","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbo.2022.100460_b0160","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-020-00948-5","article-title":"Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk","volume":"13","author":"Weisel","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.jbo.2022.100460_b0165","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jbo.2022.100460_b0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-9966-27-11","article-title":"Effect of pathologic fractures on survival in multiple myeloma patients: a case control study","volume":"27","author":"Sonmez","year":"2008","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jbo.2022.100460_b0175","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11914-017-0397-5","article-title":"Myeloma and Bone Disease","volume":"15","author":"Panaroni","year":"2017","journal-title":"Current osteoporosis reports"},{"issue":"20 Pt 2","key":"10.1016\/j.jbo.2022.100460_b0180","doi-asserted-by":"crossref","first-page":"6279s","DOI":"10.1158\/1078-0432.CCR-06-0681","article-title":"Treatment for myeloma bone disease","volume":"12","author":"Yeh","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jbo.2022.100460_b0185","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1385\/MO:23:4:431","article-title":"Bone disease in multiple myeloma","volume":"23","author":"Hjertner","year":"2006","journal-title":"Med Oncol"},{"issue":"14","key":"10.1016\/j.jbo.2022.100460_b0190","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: from biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jbo.2022.100460_b0195","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41375-020-0976-9","article-title":"Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age","volume":"35","author":"Mai","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jbo.2022.100460_b0200","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41408-018-0124-1","article-title":"Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group","volume":"8","author":"Moulopoulos","year":"2018","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/j.jbo.2022.100460_b0205","article-title":"Whole-body magnetic resonance imaging (WBMRI) versus whole-body computed tomography (WBCT) for myeloma imaging and staging","author":"Treitl","year":"2021","journal-title":"Skeletal Radiology"},{"issue":"9","key":"10.1016\/j.jbo.2022.100460_b0210","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jbo.2022.100460_b0215","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12885-020-6596-y","article-title":"Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review","volume":"20","author":"Mateos","year":"2020","journal-title":"BMC cancer"},{"key":"10.1016\/j.jbo.2022.100460_b0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1188\/11.S1.CJON.9-23","article-title":"Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board","volume":"15 Suppl(0)","author":"Miceli","year":"2011","journal-title":"Clin J Oncol Nurs"},{"issue":"4","key":"10.1016\/j.jbo.2022.100460_b0225","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2141.1982.tb03936.x","article-title":"Quantitative histology of myeloma-induced bone changes","volume":"52","author":"Valentin-Opran","year":"1982","journal-title":"British journal of haematology"},{"issue":"1","key":"10.1016\/j.jbo.2022.100460_b0230","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00223-013-9794-7","article-title":"Signaling between tumor cells and the host bone marrow microenvironment","volume":"94","author":"Kovacic","year":"2014","journal-title":"Calcified tissue international"},{"issue":"6","key":"10.1016\/j.jbo.2022.100460_b0235","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrc.2016.44","article-title":"Bone metastasis: the importance of the neighbourhood","volume":"16","author":"Croucher","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.jbo.2022.100460_b0240","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jbo.2022.100460_b0245","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jsbmb.2013.09.008","article-title":"Prevention and treatment of postmenopausal osteoporosis","volume":"142","author":"Tella","year":"2014","journal-title":"The Journal of steroid biochemistry and molecular biology"},{"issue":"2","key":"10.1016\/j.jbo.2022.100460_b0250","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40266-018-0525-7","article-title":"Denosumab: A Review in Postmenopausal Osteoporosis","volume":"35","author":"Deeks","year":"2018","journal-title":"Drugs & aging"},{"issue":"4","key":"10.1016\/j.jbo.2022.100460_b0255","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/ejh.12069","article-title":"The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling","volume":"90","author":"Kaiser","year":"2013","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.jbo.2022.100460_b0260","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12893-017-0288-9","article-title":"Oncological and functional results of the surgical treatment of vertebral metastases in patients with multiple myeloma\u201c","volume":"17","author":"Guzik","year":"2017","journal-title":"BMC Surg"},{"issue":"8","key":"10.1016\/j.jbo.2022.100460_b0265","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00264-010-1127-0","article-title":"Surgical therapy of skeletal complications in multiple myeloma","volume":"35","author":"Utzschneider","year":"2011","journal-title":"Int Orthop"},{"issue":"8","key":"10.1016\/j.jbo.2022.100460_b0270","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jbo.2022.100460_b0275","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.jbo.2022.100460_b0280","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","article-title":"Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbo.2022.100460_b0285","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","author":"Witzig","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jbo.2022.100460_b0290","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.jbo.2022.100460_b0295","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3324\/haematol.2015.128439","article-title":"Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial","volume":"100","author":"Garc\u00eda-Sanz","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.jbo.2022.100460_b0300","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ejca.2015.04.017","article-title":"The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease","volume":"51","author":"Diel","year":"2015","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.jbo.2022.100460_b0305","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jbo.2022.100460_b0310","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.25392","article-title":"Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates","volume":"94","author":"Terpos","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jbo.2022.100460_b0315","article-title":"Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results","volume":"11","author":"Fazzi","year":"2020","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jbo.2022.100460_b0320","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1007\/s12325-020-01395-x","article-title":"Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis","volume":"37","author":"Huang","year":"2020","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.jbo.2022.100460_b0325","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.jbo.2022.100460_b0330","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136869","article-title":"Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer","volume":"22","author":"Mbese","year":"2021","journal-title":"International journal of molecular sciences"},{"issue":"8","key":"10.1016\/j.jbo.2022.100460_b0335","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/imj.13502","article-title":"Bisphosphonate guidelines for treatment and prevention of myeloma bone disease","volume":"47","author":"Lee","year":"2017","journal-title":"Internal medicine journal"},{"issue":"3","key":"10.1016\/j.jbo.2022.100460_b0340","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/ejh.12239","article-title":"Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review","volume":"92","author":"Alegre","year":"2014","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.jbo.2022.100460_b0345","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11899-020-00570-9","article-title":"Supportive Care in Multiple Myeloma","volume":"15","author":"Guzdar","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.jbo.2022.100460_b0350","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","article-title":"Guidelines for supportive care in multiple myeloma 2011","volume":"154","author":"Snowden","year":"2011","journal-title":"British journal of haematology"},{"issue":"8827","key":"10.1016\/j.jbo.2022.100460_b0355","first-page":"1049","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Finnish Leukaemia Group. Lancet"},{"issue":"18","key":"10.1016\/j.jbo.2022.100460_b0360","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease","volume":"31","author":"Terpos","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.jbo.2022.100460_b0365","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jbmr.4235","article-title":"Safety of Oral Bisphosphonates in Moderate-to-Severe Chronic Kidney Disease: A Binational Cohort Analysis","volume":"36","author":"Robinson","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbo.2022.100460_b0370","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1200\/EDBK_205583","article-title":"Bones in Multiple Myeloma: Imaging and Therapy","volume":"38","author":"Zamagni","year":"2018","journal-title":"American Society of Clinical Oncology Educational Book"},{"key":"10.1016\/j.jbo.2022.100460_b0375","first-page":"8","volume":"12","author":"Rasch","year":"2020","journal-title":"Multiple Myeloma Associated Bone Disease. Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jbo.2022.100460_b0380","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/jcm10010152","article-title":"Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review","volume":"10","author":"Anastasilakis","year":"2021","journal-title":"Journal of Clinical Medicine"},{"issue":"11","key":"10.1016\/j.jbo.2022.100460_b0385","article-title":"Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis","volume":"2019","author":"Piechotta","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.jbo.2022.100460_b0390","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/cncr.28481","article-title":"The effects of bortezomib on bone disease in patients with multiple myeloma","volume":"120","author":"Mohty","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2022.100460_b0395","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.740796","article-title":"Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma","volume":"11","author":"Jayaweera","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jbo.2022.100460_b0400","doi-asserted-by":"crossref","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, et al. Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du My\u00e9Lome (IFM) Krd Phase II Study. Blood 2016; 128: 1142-.","DOI":"10.1182\/blood.V128.22.1142.1142"},{"key":"10.1016\/j.jbo.2022.100460_b0405","doi-asserted-by":"crossref","unstructured":"Zimmerman T, Raje N, Vij R, et al. Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). Blood 2016; 128: 675-.","DOI":"10.1182\/blood.V128.22.675.675"},{"issue":"22","key":"10.1016\/j.jbo.2022.100460_b0410","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood.2020007522","article-title":"Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma","volume":"136","author":"Jasielec","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jbo.2022.100460_b0415","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3389\/fimmu.2018.02467","article-title":"Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy","volume":"9","author":"Toscani","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jbo.2022.100460_b0420","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s11914-017-0403-y","article-title":"Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease","volume":"15","author":"McDonald","year":"2017","journal-title":"Current osteoporosis reports"},{"issue":"12","key":"10.1016\/j.jbo.2022.100460_b0425","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1038\/leu.2017.152","article-title":"Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth","volume":"31","author":"Delgado-Calle","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jbo.2022.100460_b0430","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","article-title":"Role and mechanism of action of sclerostin in bone","volume":"96","author":"Delgado-Calle","year":"2017","journal-title":"Bone"},{"issue":"26","key":"10.1016\/j.jbo.2022.100460_b0435","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jbo.2022.100460_b0440","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1038\/s41467-019-12296-1","article-title":"Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease","volume":"10","author":"Gooding","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.jbo.2022.100460_b0445","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1365-2141.2003.04178.x","article-title":"Infection\u2013an underappreciated cause of bone pain in multiple myeloma","volume":"120","author":"Desikan","year":"2003","journal-title":"British journal of haematology"},{"issue":"4","key":"10.1016\/j.jbo.2022.100460_b0450","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/j.1756-185X.2010.01558.x","article-title":"Unsuspected multiple myeloma presenting as Escherichia coli infectious spondylitis: a case report","volume":"13","author":"Yu","year":"2010","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"10.1016\/j.jbo.2022.100460_b0455","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/tid.12573","article-title":"Lasiodiplodia species fungal osteomyelitis in a multiple myeloma patient","volume":"18","author":"Mohan","year":"2016","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"10.1016\/j.jbo.2022.100460_b0460","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5045\/br.2016.51.4.224","article-title":"Emphysematous osteomyelitis due to Escherichia coli in multiple myeloma","volume":"51","author":"Park","year":"2016","journal-title":"Blood Res"},{"issue":"3","key":"10.1016\/j.jbo.2022.100460_b0465","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.2106\/JBJS.CC.16.00272","article-title":"Streptococcus pneumoniae Osteomyelitis in a 25-Year-Old Man as the Initial Presentation of Multiple Myeloma: A Case Report","volume":"7","author":"Webber","year":"2017","journal-title":"JBJS Case Connect"},{"issue":"3","key":"10.1016\/j.jbo.2022.100460_b0470","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.diagmicrobio.2019.02.004","article-title":"Disseminated \u201cHaemophilus quentini\u201d infection in a patient with multiple myeloma \u2013 A case report and review of the literature","volume":"94","author":"Cohen","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"7","key":"10.1016\/j.jbo.2022.100460_b0475","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.amjmed.2021.01.032","article-title":"A 77-Year-Old Man with Multiple Myeloma and a Lytic Bone Lesion","volume":"134","author":"Sassine","year":"2021","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.jbo.2022.100460_b0480","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-240404","article-title":"Oligosecretory multiple myeloma: a devastating presentation of a difficult diagnosis","volume":"14","author":"Roque","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10.1016\/j.jbo.2022.100460_b0485","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/RCT.0000000000001086","article-title":"Differentiation of Multiple Myeloma and Lytic Bone Metastases: Histogram Analysis","volume":"44","author":"Yildirim","year":"2020","journal-title":"Journal of Computer Assisted Tomography"},{"issue":"6","key":"10.1016\/j.jbo.2022.100460_b0490","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3324\/haematol.2011.054015","article-title":"Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.jbo.2022.100460_b0495","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"The Lancet Oncology"},{"issue":"6","key":"10.1016\/j.jbo.2022.100460_b0500","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","article-title":"Prophylactic antibiotics for the prevention of early infection in multiple myeloma","volume":"100","author":"Oken","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.jbo.2022.100460_b0505","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/978-3-540-85772-3_14","article-title":"Osteoplastic procedures for the treatment of vertebral complications in multiple myeloma patients","volume":"183","author":"Kasperk","year":"2011","journal-title":"Recent Results Cancer Res"},{"issue":"2","key":"10.1016\/j.jbo.2022.100460_b0510","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.oooo.2018.09.008","article-title":"Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment","volume":"127","author":"Nicolatou-Galitis","year":"2019","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"3","key":"10.1016\/j.jbo.2022.100460_b0515","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.jbo.2022.100460_b0520","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.blre.2013.08.002","article-title":"Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention","volume":"27","author":"Zhou","year":"2013","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.jbo.2022.100460_b0525","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bone.2013.01.012","article-title":"In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma","volume":"53","author":"Pozzi","year":"2013","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.jbo.2022.100460_b0530","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","article-title":"Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma","volume":"114","author":"Fulciniti","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jbo.2022.100460_b0535","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jbo.2022.100460_b0540","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"British journal of haematology"},{"issue":"6","key":"10.1016\/j.jbo.2022.100460_b0545","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jbmr.2789","article-title":"Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease","volume":"31","author":"Eda","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.jbo.2022.100460_b0550","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1172\/JCI3523","article-title":"TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development","volume":"103","author":"Yin","year":"1999","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.jbo.2022.100460_b0555","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/jbmr.3606","article-title":"Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models","volume":"34","author":"Paton-Hough","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.jbo.2022.100460_b0560","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.3747\/co.21.1798","article-title":"Bortezomib in multiple myeloma: systematic review and clinical considerations","volume":"21","author":"Kouroukis","year":"2014","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.jbo.2022.100460_b0565","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","article-title":"Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma","volume":"2","author":"Field-Smith","year":"2006","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jbo.2022.100460_b0570","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bone.2016.07.007","article-title":"Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease","volume":"91","author":"Nyman","year":"2016","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.jbo.2022.100460_b0575","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/10428194310001593193","article-title":"The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression","volume":"45","author":"Roux","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.jbo.2022.100460_b0580","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.exphem.2004.03.015","article-title":"New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL)","volume":"32","author":"Giuliani","year":"2004","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jbo.2022.100460_b0585","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/804182","article-title":"Serum parathyroid hormone is a new potential risk factor in multiple myeloma","volume":"2014","author":"Kang","year":"2014","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.jbo.2022.100460_b0590","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000509768","article-title":"Concomitant Primary Hyperparathyroidism in Patients with Multiple Myeloma: A Possible Link?","volume":"144","author":"Notarfranchi","year":"2021","journal-title":"Acta Haematologica"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137422000501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137422000501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:19:14Z","timestamp":1761941954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137422000501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":118,"alternative-id":["S2212137422000501"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2022.100460","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preventing osteolytic lesions and osteomyelitis in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2022.100460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100460"}}